Beyond randomized controlled trials: A “real life” experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab-Reference-Cited by-同舟云学术

Beyond randomized controlled trials: A “real life” experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab

Published:2006 Issue:12 Volume:41 Page:1167-1174
ISSN:8755-6863
Container-title:Pediatric Pulmonology
language:en
Short-container-title:Pediatr. Pulmonol.

Author:

Mitchell Ian,Tough Suzanne,Gillis Lynne,Majaesic Carina

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology, and Child Health

Reference22 articles.

1. Lower respiratory tract illness in the first two years of life: epidemiologic patterns and costs in a suburban pediatric practice.

2. Health Canada, PPHB. Respiratory Virus Detections/Isolations in Canada. http://www.hc-sc.gc.ca/pphb-dgspsp/bid-bmi/dsd-dsm/rvdi-divr/2003pdf/rvdi1103.pdf Report Accessed 21-3- 2003.

3. Statistics Canada, Statistics Canada. 2001. Census. http://www12.statcan.ca/english/scensus01/products/standard/themes/RetrieveProductTable.cfm Report Accessed 21-3- 2003.

4. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants

5. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study;Journal of the Pediatric Infectious Diseases Society;2020-05-29

2. Respiratory syncytial virus prophylaxis for children with chronic lung disease: have we got the criteria right?;Expert Review of Anti-infective Therapy;2019-02-26

3. Impact of the use of immunoglobulin palivizumab in the State of São Paulo: a cohort study;Revista Latino-Americana de Enfermagem;2017-09-21

4. Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis;European Journal of Clinical Microbiology & Infectious Diseases;2017-01-11

5. Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease;Pediatric Pulmonology;2016-09-12